NewAmsterdam's experimental cholesterol drug reduces presence of Alzheimer's biomarker
NewAmsterdam Pharma’s stock ticked upward on Monday after a biomarker analysis of its experimental cholesterol-lowering drug showed promise in Alzheimer’s disease. The drug, a CETP inhibitor known as obicetrapib, induced a statistically significant reduction of ...
NewAmsterdam Pharma’s stock ticked upward on Monday after a biomarker analysis of its experimental cholesterol-lowering drug showed promise in Alzheimer’s disease.
The drug, a CETP inhibitor known as obicetrapib, induced a statistically significant reduction of ...
